Reviewing Coherus BioSciences Inc. (CHRS)’s and Surface Oncology Inc. (NASDAQ:SURF)’s results

This is a contrast between Coherus BioSciences Inc. (NASDAQ:CHRS) and Surface Oncology Inc. (NASDAQ:SURF) based on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus BioSciences Inc. N/A 0.00 209.34M -3.13 0.00
Surface Oncology Inc. 59.42M 2.25 6.61M -0.54 0.00

In table 1 we can see Coherus BioSciences Inc. and Surface Oncology Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Coherus BioSciences Inc. and Surface Oncology Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Coherus BioSciences Inc. 0.00% -742.4% -126.3%
Surface Oncology Inc. -11.12% 63.7% 15.3%

Liquidity

Coherus BioSciences Inc. has a Current Ratio of 5.3 and a Quick Ratio of 5.3. Competitively, Surface Oncology Inc.’s Current Ratio is 6.4 and has 6.4 Quick Ratio. Surface Oncology Inc.’s better ability to pay short and long-term obligations than Coherus BioSciences Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Coherus BioSciences Inc. and Surface Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Coherus BioSciences Inc. 0 0 2 3.00
Surface Oncology Inc. 0 0 0 0.00

Coherus BioSciences Inc. has a 72.29% upside potential and an average price target of $25.

Institutional and Insider Ownership

Roughly 98.8% of Coherus BioSciences Inc. shares are held by institutional investors while 60.3% of Surface Oncology Inc. are owned by institutional investors. Coherus BioSciences Inc.’s share held by insiders are 0.4%. Competitively, 0.3% are Surface Oncology Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Coherus BioSciences Inc. 1.49% 11.66% 36.64% -25.41% 53.37% 66.08%
Surface Oncology Inc. -2.58% -27.65% -47.41% -54.24% 0% -1.89%

For the past year Coherus BioSciences Inc. has 66.08% stronger performance while Surface Oncology Inc. has -1.89% weaker performance.

Summary

Surface Oncology Inc. beats Coherus BioSciences Inc. on 7 of the 10 factors.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.